Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs
J. Samarin, P. Fabrowski, R. Kurilov, H. Nuskova, J. Hummel-Eisenbeiss, H. Pink, N. Li, V. Weru, H. Alborzinia, U. Yildiz, L. Grob, M. Taubert, M. Czech, M. Morgen, C. Brandstaedter, , N. Gunkel
The paper identifies antioxidant-capacity biomarkers (ACBs) that predict susceptibility to ROS-inducing drugs in lung cancer cells, showing that low ACB expression correlates with nitric oxide levels, not ROS levels.
bioRxiv · Jan 17, 2023Cancer Biology